One dose of a Pfizer-BioNTech or AstraZeneca-Oxford vaccine reduced COVID-19 infections by 65% in a study. Two doses of Pfizer's shot did so by 90%.
Insider discussed the risks and benefits of COVID-19 vaccines from AstraZeneca and Johnson & Johnson.
Denmark said it planned to use COVID-19 vaccines from Moderna and Pfizer-BioNTech instead.
Marco Cavaleri said the exact nature of the link wasn't clear, and that benefits of the AstraZeneca vaccine outweighed any side effect risks.
Reports of serious illness after the AstraZeneca vaccine doesn't mean you're in danger: it means the system that monitors side effects is working.
The EMA said AstraZeneca's vaccine was "safe and effective," but couldn't definitively rule out a link between the shot and rare forms of blood clots.
Denmark and Norway both suspended the roll out of AstraZeneca's COVID-19 vaccine, but many experts said the shot was safe.
The Oxford University COVID-19 vaccine is to begin testing its efficacy in children aged six to 17. It will be the first trial in children so young. Children are much less affected by the novel coronavirus than adults, but there is still a risk. Visit the Business section of Insider […]
UK pharma giant AstraZeneca and Oxford University are co-developing a ‘next generation’ COVID-19 vaccine. These vaccines will be designed to combat coronavirus variants, including those found in the UK and South Africa. Mene Pangalos, executive vice-president at AstraZeneca, said they’re aiming to have it ready by autumn, per Reuters. Visit […]
Media reports that AstraZeneca’s COVID-19 vaccine is less effective in older people appear to be without merit. Reports in German media outlets Handelsblatt and Bild suggested the vaccine had an efficacy rate of 10% or less for those over 65. But the reports had “mixed up” the data, the German […]
Pakistan’s regulators approved AstraZeneca and Oxford University’s COVID-19 shot for emergency use. The shot will first be given to over-65s and healthcare workers, per The Associated Press. Local governments and private firms were free to import the shot, reported Dawn, a local newspaper. Visit Business Insider’s homepage for more stories. […]
AstraZeneca’s stock rose on Wednesday after the UK authorised the vaccine it created with Oxford University. It is the second vaccine authorised for emergency use in the UK, after Pfizer and BioNTech’s. AstraZeneca’s vaccine is easy to store and requires standard refrigeration. Other COVID-19 shots need cold storage. One chief […]
The COVID-19 vaccine being developed by AstraZeneca and the University of Oxford will be combined with Russia’s Sputnik V shot, which the country has already authorised for emergency use. In a press release on Friday, AstraZeneca said that it would “soon begin exploring” combining its shot with one made by […]
AstraZeneca is the first COVID-19 vaccine-maker to publish results from late-stage trials in a peer-reviewed journal. The results, published in the Lancet on Tuesday, suggest the vaccine’s efficacy is 70%, on average. The data confirmed preliminary results announced on November 23. The shot hasn’t been signed off by regulators, but […]
On Monday, AstraZeneca and The University of Oxford released results for their large-scale trial, which showed their COVID-19 vaccine was 70% effective. The Oxford vaccine is administered in two doses at least one month apart, similar to both Pfizer’s and Moderna’s vaccines. The vaccine is being sold far cheaper than […]
The University of Oxford and AstraZeneca’s COVID-19 vaccine can be stored at normal fridge temperatures for at least six months. Unlike Pfizer and BioNTech’s vaccine, it therefore doesn’t require an ultra-cold storage and transport system, making it cheaper to distribute globally. The price per dose is also far cheaper than […]
Shares in AstraZeneca slid 2% on Monday after the company released results that showed its COVID-19 vaccine is just 70% effective, compared with rates of above 90% for those of its two biggest rivals. The Oxford/AstraZeneca vaccine is cheaper to produce and easier to transport than those of US peers […]